Guru Fundamental Report for BMY

Bristol-Myers Squibb (BMY) has received an 88% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's academically-derived strategy for identifying low book-to-market stocks with sustained growth potential. This high score, indicating significant interest, stems from BMY's strong fundamental performance across most criteria, although it notably failed the Research and Development to Assets test. The analysis suggests BMY's underlying fundamentals and valuation are attractive for growth-focused portfolios.

Analysis

Bristol-Myers Squibb (BMY) registers as a compelling large-cap growth stock according to Validea's P/B Growth Investor model, which is based on the academic strategy of Partha Mohanram. The company achieved a high rating of 88%, indicating significant interest based on the model's criteria for identifying low book-to-market stocks with characteristics of sustained future growth. BMY's fundamental strength is evident as it passed eight key tests, including those for its book-to-market ratio, return on assets (ROA), and cash flow from operations relative to assets. The model also positively assessed the stability of its ROA and sales, as well as its capital and advertising expenditure levels. However, the analysis reveals a notable weakness, as BMY failed the test for Research and Development to Assets. This specific failure presents a key counterpoint in an otherwise strong quantitative profile, suggesting a potential underinvestment in R&D relative to its asset base, a critical factor for long-term growth in the biotechnology sector.

Key Decisions for Investors

• Investors employing quantitative growth strategies should note BMY's high score of 88% and its strong performance on profitability and cash flow metrics, suggesting it is fundamentally attractive from this model's perspective.
• The failure on the Research and Development to Assets metric is a significant flag that warrants deeper due diligence into the company's innovation pipeline and R&D strategy, as this is a primary long-term value driver in the pharmaceutical industry.
• Consider this model-based analysis as a starting point, and supplement it with qualitative assessments of BMY's drug pipeline, recent clinical trial results, and management's outlook on R&D spending before adjusting positions.